As the Founder and Chief Executive of Seattle Genetics, Inc., Clay Siegall, Ph.D., is passionate about finding cures for diseases. His goal at Seattle Genetics is to find cures to diseases, particularly cancer, which haven’t seen any meaningful decrease in mortality rates over the years. He attended the University of Maryland, earning a B.S. in Zoology, and George Washington Univerity where he garnered his Ph.D. in Genetics.
Before founding Seattle Genetics, Dr. Clay Seigall worked for Bristol-Myers Squibb as a senior researcher. He founded his own company because he had two main problems working for a company. The first was that he lacked the autonomy and had problems with constraints that led to him not being as effective a researcher as he could be. Secondly, it got to him that some of his drugs made $80 million or more for the company and he didn’t get any of that profit outside of his regular paycheck. He decided to become his own boss so he could be more effective and earn more money from his ingenuity.
Dr. Clay Seigall has said that the old way of treating diseases such as cancer are coming to an end. Old treatments, such as non-targeted drugs and chemotherapy, aren’t nearly as effective as new methods and they are very harmful to the patient’s body. Drugs that he and others develop, such as his use of antibody-drug conjugates, directly attack cancer cells while leaving healthy cells alone. This way of treating disease will increasingly take over in the future.
In addition to his highly successful leadership at Seattle Genetics, Dr. Siegall is sought out as a biotechnology industry expert. He serves on the Board of Directors for Mirna Therapeutics, Inc. which is a firm that specializes in microRNA therapeutics. In February 2014 he was also named to the board of Ultragenyx Pharmaceutical Inc. This company focuses on finding cures for rare and ultra-rare diseases that affect people around the world. He is also on the Board of Directors of Alder BioPharmaceuticals, Inc. which creates genetically engineered therapeutic antibodies.